Description

A focused course, tailored for you

Cell Line Engineering CMC: From Vial to IND Submission

The CMC workbook for cell line engineering scientists moving an engineered candidate from research bank to IND-ready filing.

You engineered the line. Regulatory affairs needs the CMC packet, the comparability story, and the potency justification. Translating bench science into a CBER-ready Module 3 is a different skill from running the experiments.

$199 one-time

Tailored to your situation. Access within 24 hours. 30-day money-back.

Includes a hand-built implementation playbook delivered alongside course access, generated for your specific situation.

Why this course

Cell line engineering scientists working on cell therapy and regenerative medicine candidates sit at a difficult intersection. The wet-lab work produces the engineered line, the characterisation data, the stability runs, and the process improvements. The IND filing demands all of that as structured Module 3 chemistry, manufacturing, and controls content with cross-references to FDA Cellular and Gene Therapy guidances, 21 CFR 1271 donor eligibility for the source material, ICH Q5A R2 viral safety expectations for the cell substrate and raw materials of biological origin, and ICH Q5E comparability when the process changes between research, engineering, and GMP runs. The CMC writer or regulatory affairs lead asks for the cell bank characterisation summary, the genetic stability data, the potency matrix with a justified release assay, the comparability protocol, the in-process control rationale, the raw material qualification trail, and the container closure justification. None of that is in the lab notebook in the shape the reviewer needs it. The gap between the scientist's data and the reviewer-ready Module 3 is where IND timelines slip by quarters.

What you walk away with

Build a cell bank characterisation summary that satisfies the CBER reviewer expectations for an engineered cell therapy candidate.
Justify a release potency assay with a defensible matrix rather than a single surrogate marker.
Author a comparability protocol covering the process change between research, engineering, and GMP runs.
Map your raw materials and starting material to 21 CFR 1271 donor eligibility and ICH Q5A R2 viral safety expectations.
Walk into a pre-IND meeting able to answer CMC questions on your candidate without deferring to regulatory affairs.

The 12 modules

Module 1. The cell therapy CMC architecture and where your engineered line sits in it

Module 3 of an IND for an engineered cell therapy candidate is organised around the source material, the cell substrate, the engineering modality, the manufacturing process, and the drug product. This module walks the full Module 3 table of contents for an autologous and an allogeneic example, locates exactly where your engineering work feeds in, and shows how research-lab artefacts get translated into the structured sections a CBER reviewer reads first.

Module 2. Source material and 21 CFR 1271 donor eligibility for engineered cell therapies

Donor eligibility traceability is one of the first questions a reviewer raises. This module covers the 21 CFR 1271 framework for human cells, tissues, and cellular and tissue-based products, the donor eligibility determination workflow, the required communicable disease testing panel, the documentation a manufacturing partner must hand back to you, and how to handle gaps when working from older research banks where the donor records are thin.

Module 3. Master and working cell bank characterisation for an engineered line

The cell bank characterisation summary is the foundation of your CMC story. This module covers identity testing for the engineered line, transgene integrity and copy number, genetic stability across the manufacturing window, sterility, mycoplasma, adventitious agent testing aligned to ICH Q5A R2, and tumourigenicity considerations for iPSC-derived candidates. Worked example for an engineered T cell bank and an allogeneic iPSC-derived bank.

Module 4. Vector and engineering modality characterisation feeding the cell substrate story

Whether the engineering uses a lentiviral vector, a CRISPR Cas9 ribonucleoprotein, a base editor, or a non-viral integration approach, the characterisation feeds directly into the cell substrate Module 3.2.S sections. This module walks vector or editor characterisation expectations, off-target assessment for gene-edited candidates, integration site analysis where required, and how to scope the characterisation work to the actual risk profile of your modality.

Module 5. Potency assay strategy beyond viability and surface markers

Reviewers reject potency matrices that lean on viability and a single surface marker. This module builds a potency matrix that ties mechanism of action to a quantitative biological readout, walks the FDA potency assay guidance for cell and gene therapy products, covers bridging from a research assay to a release assay, and shows how to phase the matrix from IND through pivotal trial. Worked example for a CAR-T potency story and a regenerative medicine functional potency story.

Module 6. Process development, process change, and ICH Q5E comparability for your candidate

Between the research run that generated your characterisation data and the GMP run that will supply the first-in-human trial, the process will have changed. This module covers the ICH Q5E comparability framework applied to cell therapy candidates, the comparability protocol structure, the analytical, functional, and safety attributes a reviewer expects to see compared, and the bridging strategy when the engineered line is the constant but the manufacturing site or scale changes.

Module 7. Raw materials of biological origin and ancillary material qualification

Fetal bovine serum, human AB serum, cytokines, growth factors, beads, electroporation reagents, and culture media all need qualification trails that show up in Module 3. This module covers the raw material qualification framework for ancillary materials used in cell therapy manufacturing, the USP 1043 ancillary material risk tier approach, vendor qualification expectations, and the documentation package a reviewer will ask for when a high-risk ancillary material appears in your process.

Module 8. In-process controls and release specifications for an engineered cell therapy

In-process controls anchor the manufacturing story. Release specifications anchor the product story. This module walks the structure of an IPC and release specification table for an engineered cell therapy candidate, the difference between IND-enabling and pivotal-stage specifications, how to set provisional acceptance criteria from limited batches, and how to defend a wide range at IND with a tightening plan.

Module 9. Stability programme design for a cell therapy drug product

Cell therapy stability does not look like small molecule or monoclonal antibody stability. This module covers the stability programme structure for cryopreserved cell therapy products, accelerated and real-time arms, in-use stability for thaw and infusion windows, the role of forced degradation, container closure compatibility, and the data shape a CMC writer needs to populate Module 3.2.P.8.

Module 10. Container closure, fill-finish, and cold chain for the drug product

The drug product is only as good as the vial it ships in and the temperature trail it survives. This module covers cryobag and vial selection for cell therapy products, extractables and leachables expectations at IND, fill-finish qualification, the cold chain validation expectations from manufacturing site to clinical site, and the chain of custody and chain of identity controls that CBER reviewers now expect.

Module 11. CMC sections of the pre-IND meeting briefing book and pre-IND questions

Pre-IND is the moment to surface CMC gaps before they cost a quarter. This module walks the CMC content of a pre-IND meeting briefing book for a cell therapy candidate, the CMC questions worth asking, how to scope characterisation work after the FDA response, and the difference between a productive pre-IND meeting and one that returns a list of clinical hold risks. Worked example uses a real-shape briefing book outline.

Module 12. Building and defending the Module 3 narrative through to IND clearance

The final module brings the previous eleven together into a Module 3 narrative for your specific candidate. The cell substrate story, the engineering story, the process story, the comparability story, the potency story, the stability story, the container closure story. This module covers cross-referencing across Module 3 sections, the common deficiency letter patterns CBER issues for cell therapy INDs, and how to author a Module 3 that survives the first review cycle without a clinical hold.

How this addresses your situation

Specific modules that map to what you said you are dealing with.

Pre-IND meeting in the next quarter and the CMC briefing book outline needs to ship to regulatory affairs.

First IND filing for an engineered cell therapy candidate where the cell substrate documentation is thin.

Process change between research and GMP runs and the comparability protocol has not been written.

CMC amendment to an existing IND where the potency assay matrix has been challenged by FDA.

What you get with this course

Twelve text-based modules in the Art of Service learning environment.
Downloadable templates for cell bank characterisation summary, comparability protocol, potency matrix, raw material qualification trail, and pre-IND briefing book CMC sections.
Worked examples for an autologous CAR-T candidate and an allogeneic iPSC-derived candidate.
The hand-built implementation playbook delivered alongside course access, tuned to whether the candidate is autologous, allogeneic, or gene-edited primary cell.
30-day money-back if the materials do not move your CMC packet forward.
Account in the learning environment provisioned alongside the playbook delivery.

What you will have in hand by Day 1, Week 1, Month 1

Within 24 hours your account in the learning environment is provisioned and the tailored implementation playbook is delivered alongside it.

Twelve modules are available immediately and can be worked in any order.

Templates are downloadable from each module page and the playbook PDF together.

Before and after

Before

You produce the characterisation data and hand it to regulatory affairs hoping they shape it into a Module 3 narrative that survives review. The pre-IND briefing book CMC section is written by someone who has never run the line. Your potency matrix is one surface marker and a viability number.

After

You own the Module 3 narrative for your engineered line. The cell bank characterisation summary, the potency matrix, the comparability protocol, the raw material qualification trail, and the pre-IND briefing book CMC sections come from you. Regulatory affairs polish the structure rather than guess at the science.

What happens if you do not address this

First-cycle clinical hold letters from CBER on cell therapy INDs cluster around the same CMC gaps: thin cell bank characterisation, weak potency justification, missing comparability for an obvious process change, and unqualified raw materials of biological origin. Each gap costs a quarter on the IND clock. The candidate program loses runway. The scientist closest to the line is the person best placed to close those gaps and rarely the person doing so.

Who it is for

You are a cell line engineering, cell therapy, or regenerative medicine scientist with a strong wet-lab and characterisation background. You have built engineered cell lines for an autologous, allogeneic, or iPSC-derived therapeutic candidate and you are now being pulled into IND preparation, pre-IND meeting prep, or a CMC amendment. You read the relevant FDA guidances but the gap between guidance and your specific candidate is unclear. You want to take ownership of the CMC story for your line rather than handing data over to regulatory affairs and hoping they shape it correctly.

Who this is NOT for. Not for clinical operations leads, manufacturing site QA managers without a cell line characterisation background, or business development staff. Not a generic FDA submissions overview. Not for vector engineering specialists who never touch the cell substrate side.

How it arrives

Text-based course in the Art of Service learning environment, plus downloadable templates and worked examples for every module, plus the hand-built implementation playbook delivered alongside course access.

Time investment. Plan 6 to 10 hours across the twelve modules if you are working a candidate through pre-IND in the next quarter. The implementation playbook is a working document, not a reading exercise. Most readers use it as the structural template for their actual Module 3 sections.

Why $199 is the right number

Free CBER and FDA guidance documents cover the regulatory expectations but do not translate them to your specific engineered line. Generic CMC training courses cover small molecule and monoclonal antibody filings with a cell therapy chapter bolted on. Consulting engagements with cell therapy CMC firms run from twenty thousand USD upward for the same scope this course covers. The course sits where the scientist closest to the line needs it: structured enough to build the actual Module 3 artefacts, specific enough to cell therapy to be worth reading.

FAQ

I work on an iPSC-derived allogeneic candidate. Is this still relevant?

Yes. Modules 3, 5, 6, and 12 carry worked examples that include the iPSC-derived allogeneic case alongside the autologous CAR-T case. The implementation playbook is tuned to whichever modality your candidate is.

I am not the regulatory affairs lead. Should regulatory take this course instead?

Regulatory affairs leads benefit, but the course is built for the scientist closest to the engineered line. The CMC story collapses when the scientist hands data over without shaping the narrative. The course is built to put the scientist back in ownership of Module 3.

How current is the regulatory content?

Built against the current FDA Cellular and Gene Therapy guidance suite, ICH Q5A R2, ICH Q5E, 21 CFR 1271, USP 1043, and the current CBER pre-IND meeting process. Updates are pushed to the learning environment when guidances revise.

Does it cover gene editing modalities?

Yes. Module 4 covers vector-based and gene-editing modalities including CRISPR Cas9 ribonucleoprotein and base editor approaches, with off-target assessment expectations and integration site analysis where required.

30-day money-back guarantee. If after a week of working through the materials this is not what you needed, reply to the receipt email and a full refund is processed. No questions, no forms.

Within 24 hours your account in the learning environment is provisioned and the tailored implementation playbook is delivered alongside it.